Frederick “Eric” Arnold, PhD, on Investigating Alternative Polyadenylation in ALS Models

Commentary
Video

The postdoctoral scholar at University of California – Irvine discussed his research looking at TDP-43 and alternative polyadenylation in neuronal cells.

“Alternative polyadenylation is something that TDP-43 had previously been shown to regulate, but it hadn't been studied in the context of ALS. Basically, following up on other great work that has been done to better understand TDP-43 function, we characterized changes in alternative polyadenylation that are regulated by TDP-43 in the context of neuronal cells and ALS.”

Amyotrophic lateral sclerosis (ALS) is currently associated with genes including SOD1 and C9orf72, however, these cases with known genetic causes only make up around 5-10% of ALS cases. New research by Frederick “Eric” Arnold, PhD, postdoctoral scholar, University of California – Irvine, and colleagues has focused on looking at the TDP-43 protein, and how changes in alternative polyadenylation that are regulated by TDP-43 affect neuronal cells and ALS.

Arnold discussed the ongoing research during a session entitled "Translational research in ALS: Novel Biomarkers and Model Systems" at the 2024 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference, held March 3-6, in Orlando. CGTLive® spoke with Arnold to learn more about TDP-43, alternative polyadenylation, and the effects of alternative polyadenylation in neuronal cells. He also overviewed research with TDP-43 that has been done so far.

Click here to view more coverage of the 2024 MDA Conference.

REFERENCES
1. Arnold F. Characterization of Alternative Polyadenylation Events in ALS Highlights New Disease Mechanisms and Novel Gene Therapy Targets. Presented at: 2024 MDA Clinical and Scientific Conference; March 3-6; Orlando, FL.
2. Amyotrophic Lateral Sclerosis (ALS): Causes/Inheritance. MDA website. https://www.mda.org/disease/amyotrophic-lateral-sclerosis/causes-inheritance#:~:text=About%205%2D10%25%20of%20ALS,specific%20region%20of%20a%20chromosome.
Recent Videos
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Sarah Larson, MD, the medical director of the Immune Effector Cell Therapy Program in the Division of Hematology/Oncology at David Geffen School of Medicine at University of California, Los Angeles (UCLA)
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
Related Content
© 2025 MJH Life Sciences

All rights reserved.